That passphrase isn't right. Check your invitation email, or contact harry.massey@e4l.com.
Confidential. For accredited investors only. Securities offered under Rule 506(c) of Regulation D; accredited status is verified before any subscription is accepted. Site access is granted by E4L, Inc.
Original documents, written for E4L — the investment case, the numbers, the deal, the science, the team and the industry thesis — plus the four documents you sign to invest. Open any one and print it to PDF. Everything is here on the site — the full set, in one place.
Each is a self-contained page — click Open / Print to PDF to read it, then use your browser's print dialog to save a PDF.
What E4L is, what was acquired (XPO Health / NES Health), the six revenue lines, the numbers, the raise, and the team & board — in two pages.
The annual P&L to net income, the cash-flow statement and the balance sheet (model v2.6), the drivers in plain English, the day-one revenue base, and the downside case — $2.7M (Q4 2026) to $134.7M by FY2031.
Formation → post-SAFE tables, the 50:50 founder block, the 14% phantom pool (no options), and why founder control comes from majority ownership plus board-designation rights.
The SAFE in plain English: $5M raise, $73M post-money cap + 15% discount, no tranches — you convert at the lower of the two, so your effective entry likely sits between ~$60M and $73M.
A one-page orientation to what the Memorandum covers. The full Memorandum is provided to every investor and must be acknowledged before signing.
The quarter-by-quarter launch plan, the ten-metric board KPI pack, and the AI-assisted operating cadence behind it.
Three evidence tiers with limitations stated on the page, the EXPLORE publication (with DOI), the patent phrasing and the four books.
The six leaders, the board (Harry Massey and Susan Kichuk, with one seat open), the advisors, the org shape and the hiring plan.
The industry thesis in full — Harry Massey's essay on why the next era of health is built on the body's measurable physics, and where E4L sits in it.
One 1× non-participating preference for cash actually invested — new money senior, founder's own capital junior — worked through $30M, $150M and $1B exits. Cash back first, then shared upside.
Product & Technology overview — what E4L makes, how the FIELD platform and the products work, and the roadmap.
Market overview (sourced sector figures) — the markets E4L operates in and where it sits within them.
Use of Funds & milestones — where the $5M goes, and the milestones it buys.
IP & chain-of-title — what the Company owns and how each asset reaches it.
Corporate & formation summary — the entity, share classes and formation facts in one place.
These documents are illustrative and forward-looking, based on management assumptions; they are not legal, tax or financial advice, and actual results will differ. The Disclosure Memorandum and the executed SAFE govern.
The four documents you complete to invest. Each opens as a self-contained page — read it, then print or save it to PDF to sign. Nothing is executed until you and the Company countersign; the step-by-step path is on the Close page.
Completed and returned first — it confirms your accredited status and, for entities, signatory authority.
The controlling document for the offering, including the risk factors. You sign an acknowledgment before any SAFE is issued.
The instrument itself — SAFE (YC style), $73M post-money cap + 15% discount. Your investment amount is entered before signature.
The optional elections — pro-rata rights and the IP-vesting repayment covenant — signed alongside the SAFE if you elect them.
The forecast is built bottoms-up from confirmed unit economics, and now carries all three statements — P&L to net income (with a blended ~25% tax provision), a full cash-flow statement, and a balance sheet that balances in every quarter with no debt anywhere on it. The company starts with real revenue: the acquired practitioner base's infoceutical wholesale was running at ≈$3.5M/yr at close (2026) — the model's opening input. The legacy NES Health entity balance sheet will be added on receipt and is available on request.
Model v2.6 (July 2026) · quarterly, Q3 2026–Q4 2031 · P&L to net income, cash-flow statement and balance sheet · forward-looking only.
The step-by-step chain-of-title status table — which asset-purchase and IP-assignment documents are signed and which are completing — and the full related-party detail are set out in the Disclosure Memorandum, with a one-page orientation in the Memorandum summary. The Company owns the FIELD diagnostic platform and the products outright, through the acquired NES Health LLC and Energy 4 Life LLC subsidiaries.
The granted UK patent (2024) and the corresponding US application (2022), the peer-reviewed UCSD / EXPLORE publication (with DOI), and the four books are summarized in the Science & Evidence Summary, with the full industry thesis in The Physics-First Healthcare Transition.
The terms are on the Deal page; the closing steps are on the Close page. Questions on anything here — ask Harry directly.